These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
333 related articles for article (PubMed ID: 32467323)
1. Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: the first multicentre, phase III trial in China. Zheng H; Yang Y; Chen H; Li C; Chen Y; Shi FD; Yang L; Cui X; Lu Z; Liang Y; Cui S; Xu A; Wu Y; Sun Y; Wang Y Stroke Vasc Neurol; 2020 Sep; 5(3):285-290. PubMed ID: 32467323 [TBL] [Abstract][Full Text] [Related]
2. Lipid-Lowering Pretreatment and Outcome Following Intravenous Thrombolysis for Acute Ischaemic Stroke: A Post Hoc Analysis of the Enhanced Control of Hypertension and Thrombolysis Stroke Study Trial. Minhas JS; Wang X; Arima H; Bath PM; Billot L; Broderick JP; Donnan GA; Kim JS; Lavados PM; Lee TH; Martins SCO; Olavarría VV; Pandian JD; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Thang NH; Wang JG; Woodward M; Chalmers J; Anderson CS; Robinson TG; Cerebrovasc Dis; 2018; 45(5-6):213-220. PubMed ID: 29705803 [TBL] [Abstract][Full Text] [Related]
3. Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. Cheng JW; Zhang XJ; Cheng LS; Li GY; Zhang LJ; Ji KX; Zhao Q; Bai Y J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):381-390. PubMed ID: 29111341 [TBL] [Abstract][Full Text] [Related]
4. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. Huang X; Cheripelli BK; Lloyd SM; Kalladka D; Moreton FC; Siddiqui A; Ford I; Muir KW Lancet Neurol; 2015 Apr; 14(4):368-76. PubMed ID: 25726502 [TBL] [Abstract][Full Text] [Related]
5. Interaction of Blood Pressure Lowering and Alteplase Dose in Acute Ischemic Stroke: Results of the Enhanced Control of Hypertension and Thrombolysis Stroke Study. Wang X; Song L; Yang J; Sun L; Moullaali TJ; Sandset EC; Delcourt C; Lindley RI; Robinson TG; Minhas JS; Arima H; Chalmers J; Kim JS; Sharma V; Wang JG; Pontes-Neto O; Lavados PM; Olavarría VV; Lee TH; Levi C; Martins SO; Thang NH; Anderson CS; Cerebrovasc Dis; 2019; 48(3-6):207-216. PubMed ID: 31812956 [TBL] [Abstract][Full Text] [Related]
6. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial. Kvistad CE; Næss H; Helleberg BH; Idicula T; Hagberg G; Nordby LM; Jenssen KN; Tobro H; Rörholt DM; Kaur K; Eltoft A; Evensen K; Haasz J; Singaravel G; Fromm A; Thomassen L Lancet Neurol; 2022 Jun; 21(6):511-519. PubMed ID: 35525250 [TBL] [Abstract][Full Text] [Related]
7. Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. Zinkstok SM; Roos YB; Lancet; 2012 Aug; 380(9843):731-7. PubMed ID: 22748820 [TBL] [Abstract][Full Text] [Related]
8. MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset. Thomalla G; Simonsen CZ; Boutitie F; Andersen G; Berthezene Y; Cheng B; Cheripelli B; Cho TH; Fazekas F; Fiehler J; Ford I; Galinovic I; Gellissen S; Golsari A; Gregori J; Günther M; Guibernau J; Häusler KG; Hennerici M; Kemmling A; Marstrand J; Modrau B; Neeb L; Perez de la Ossa N; Puig J; Ringleb P; Roy P; Scheel E; Schonewille W; Serena J; Sunaert S; Villringer K; Wouters A; Thijs V; Ebinger M; Endres M; Fiebach JB; Lemmens R; Muir KW; Nighoghossian N; Pedraza S; Gerloff C; N Engl J Med; 2018 Aug; 379(7):611-622. PubMed ID: 29766770 [TBL] [Abstract][Full Text] [Related]
9. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial. Anderson CS; Huang Y; Lindley RI; Chen X; Arima H; Chen G; Li Q; Billot L; Delcourt C; Bath PM; Broderick JP; Demchuk AM; Donnan GA; Durham AC; Lavados PM; Lee TH; Levi C; Martins SO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Silva F; Song L; Thang NH; Wardlaw JM; Wang JG; Wang X; Woodward M; Chalmers J; Robinson TG; Lancet; 2019 Mar; 393(10174):877-888. PubMed ID: 30739745 [TBL] [Abstract][Full Text] [Related]
10. Renal Dysfunction Associated with Symptomatic Intracranial Hemorrhage after Intravenous Thrombolysis. Zhu J; Shen X; Han C; Mei C; Zhou Y; Wang H; Kong Y; Jiang Y; Fang Q; Cai X J Stroke Cerebrovasc Dis; 2019 Nov; 28(11):104363. PubMed ID: 31501038 [TBL] [Abstract][Full Text] [Related]
11. TESPI (Thrombolysis in Elderly Stroke Patients in Italy): a randomized controlled trial of alteplase (rt-PA) versus standard treatment in acute ischaemic stroke in patients aged more than 80 years where thrombolysis is initiated within three hours after stroke onset. Lorenzano S; Toni D; Int J Stroke; 2012 Apr; 7(3):250-7. PubMed ID: 22292526 [TBL] [Abstract][Full Text] [Related]
12. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. Hacke W; Kaste M; Bluhmki E; Brozman M; Dávalos A; Guidetti D; Larrue V; Lees KR; Medeghri Z; Machnig T; Schneider D; von Kummer R; Wahlgren N; Toni D; N Engl J Med; 2008 Sep; 359(13):1317-29. PubMed ID: 18815396 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of Tirofiban Administered at Different Time Points after Intravenous Thrombolytic Therapy with Alteplase in Patients with Acute Ischemic Stroke. Liu J; Shi Q; Sun Y; He J; Yang B; Zhang C; Guo R J Stroke Cerebrovasc Dis; 2019 Apr; 28(4):1126-1132. PubMed ID: 30655038 [TBL] [Abstract][Full Text] [Related]
14. Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: trial reanalysis adjusted for baseline imbalances. Alper BS; Foster G; Thabane L; Rae-Grant A; Malone-Moses M; Manheimer E BMJ Evid Based Med; 2020 Oct; 25(5):168-171. PubMed ID: 32430395 [TBL] [Abstract][Full Text] [Related]
15. Treatment with intravenous alteplase in ischaemic stroke patients with onset time between 4.5 and 24 hours (HOPE): protocol for a randomised, controlled, multicentre study. Luo Z; Zhou Y; He Y; Yan S; Chen Z; Zhang X; Chen Y; Tong LS; Zhong W; Hu H; Zhang K; Yang J; Campbell BCV; Lou M Stroke Vasc Neurol; 2024 Jun; 9(3):318-323. PubMed ID: 37527920 [TBL] [Abstract][Full Text] [Related]
16. Symptomatic intracerebral hemorrhage after intravenous thrombolysis in Chinese patients: comparison of prediction models. Li M; Wang-Qin RQ; Wang YL; Liu LB; Pan YS; Liao XL; Wang YJ; Xu AD J Stroke Cerebrovasc Dis; 2015 Jun; 24(6):1235-43. PubMed ID: 25891755 [TBL] [Abstract][Full Text] [Related]
17. Characteristics, management and response to alteplase in China versus non-China participants of the ENCHANTED trial. Song L; Wang X; Robinson T; Lindley RI; Arima H; Lavados PM; Chen X; Chalmers J; Anderson CS Stroke Vasc Neurol; 2017 Jun; 2(2):53-58. PubMed ID: 28959492 [TBL] [Abstract][Full Text] [Related]
18. A matched comparison of eptifibatide plus rt-PA versus rt-PA alone in acute ischemic stroke. Adeoye O; Knight WA; Khoury J; Schmit PA; Sucharew H; Broderick JP; Pancioli AM; J Stroke Cerebrovasc Dis; 2014; 23(5):e313-5. PubMed ID: 24534128 [TBL] [Abstract][Full Text] [Related]
19. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Emberson J; Lees KR; Lyden P; Blackwell L; Albers G; Bluhmki E; Brott T; Cohen G; Davis S; Donnan G; Grotta J; Howard G; Kaste M; Koga M; von Kummer R; Lansberg M; Lindley RI; Murray G; Olivot JM; Parsons M; Tilley B; Toni D; Toyoda K; Wahlgren N; Wardlaw J; Whiteley W; del Zoppo GJ; Baigent C; Sandercock P; Hacke W; Lancet; 2014 Nov; 384(9958):1929-35. PubMed ID: 25106063 [TBL] [Abstract][Full Text] [Related]
20. Comparative Analysis on Low- and Standard-Dose Regimes of Alteplase Thrombolytic Therapy for Acute Ischemic Stroke: Efficacy and Safety. Zhao G; Huang T; Zheng M; Cui Y; Liu Y; Cheng Z; Wang Z Eur Neurol; 2018; 79(1-2):68-73. PubMed ID: 29241193 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]